PL3117709T3 - Terapia skojarzona do leczenia raka piersi - Google Patents

Terapia skojarzona do leczenia raka piersi

Info

Publication number
PL3117709T3
PL3117709T3 PL16166917T PL16166917T PL3117709T3 PL 3117709 T3 PL3117709 T3 PL 3117709T3 PL 16166917 T PL16166917 T PL 16166917T PL 16166917 T PL16166917 T PL 16166917T PL 3117709 T3 PL3117709 T3 PL 3117709T3
Authority
PL
Poland
Prior art keywords
breast cancer
combination therapy
treating breast
treating
therapy
Prior art date
Application number
PL16166917T
Other languages
English (en)
Inventor
Jay Harper
Scott Michael Lonning
Frank James Hsu
Original Assignee
Genzyme Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corporation filed Critical Genzyme Corporation
Publication of PL3117709T3 publication Critical patent/PL3117709T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL16166917T 2010-03-12 2011-03-08 Terapia skojarzona do leczenia raka piersi PL3117709T3 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US31351510P 2010-03-12 2010-03-12
EP14187507.0A EP2835053B1 (en) 2010-03-12 2011-03-08 Combination therapy for treating breast cancer
EP11753944.5A EP2544541B1 (en) 2010-03-12 2011-03-08 Combination therapy for treating breast cancer
PCT/US2011/027589 WO2011112609A1 (en) 2010-03-12 2011-03-08 Combination therapy for treating breast cancer
EP16166917.1A EP3117709B1 (en) 2010-03-12 2011-03-08 Combination therapy for treating breast cancer

Publications (1)

Publication Number Publication Date
PL3117709T3 true PL3117709T3 (pl) 2019-01-31

Family

ID=44563812

Family Applications (2)

Application Number Title Priority Date Filing Date
PL16166917T PL3117709T3 (pl) 2010-03-12 2011-03-08 Terapia skojarzona do leczenia raka piersi
PL14187507.0T PL2835053T3 (pl) 2010-03-12 2011-03-08 Terapia skojarzona do leczenia raka piersi

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL14187507.0T PL2835053T3 (pl) 2010-03-12 2011-03-08 Terapia skojarzona do leczenia raka piersi

Country Status (17)

Country Link
US (3) US8911736B2 (pl)
EP (4) EP3117709B1 (pl)
JP (2) JP5917418B2 (pl)
CY (1) CY1117831T1 (pl)
DK (2) DK2835053T3 (pl)
ES (2) ES2694288T3 (pl)
HR (2) HRP20160932T1 (pl)
HU (2) HUE040107T2 (pl)
LT (1) LT3117709T (pl)
ME (1) ME02464B (pl)
PL (2) PL3117709T3 (pl)
PT (2) PT2835053T (pl)
RS (2) RS57942B1 (pl)
SI (2) SI2835053T1 (pl)
SM (1) SMT201600253B (pl)
TR (1) TR201816180T4 (pl)
WO (1) WO2011112609A1 (pl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR201816180T4 (tr) * 2010-03-12 2018-11-21 Genzyme Corp Meme kanserini tedavi etmek için kombinasyonlu tedavi.
US9782452B2 (en) * 2011-11-22 2017-10-10 Cornell University Methods for stimulating hematopoietic recovery by inhibiting TGFβ signaling
PL2971048T4 (pl) 2013-03-11 2019-05-31 Genzyme Corp Zmodyfikowane przeciwciała anty-TGF-beta i fragmenty wiążące antygen
WO2016094697A2 (en) 2014-12-10 2016-06-16 The Regents Of The University Of Colorado, A Body Corporate Targeting breast cancer therapy based on stromal subtypes and cd146 composition
GB201503438D0 (en) 2015-02-27 2015-04-15 Ucl Business Plc Antibodies
WO2016149434A1 (en) * 2015-03-18 2016-09-22 Med-El Elektromedizinische Geraete Gmbh Fixation of a bone conduction floating mass transducer
KR102647231B1 (ko) 2018-08-02 2024-03-13 삼성전자주식회사 반도체 소자 및 이의 제조방법

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US247550A (en) * 1881-09-27 Bakee beos
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
CA1327358C (en) 1987-11-17 1994-03-01 Morio Fujiu Fluoro cytidine derivatives
FI906411A7 (fi) 1988-06-28 1990-12-27 La Jolla Cancer Res Foundation Solujen lisääntymisen esto Decorinilla
US5654270A (en) 1988-06-28 1997-08-05 La Jolla Cancer Research Foundation Use of fibromodulin to prevent or reduce dermal scarring
US5705609A (en) 1988-06-28 1998-01-06 La Jolla Cancer Research Foundation Decorin fragments inhibiting cell regulatory factors
US5583103A (en) 1988-06-28 1996-12-10 La Jolla Cancer Research Foundation Inhibition of transforming growth factor beta activity
US5571714A (en) 1988-12-22 1996-11-05 Celtrix Pharmaceuticals, Inc. Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use
ES2083469T3 (es) 1989-11-22 1996-04-16 Genentech Inc Peptido asociado a una latencia y utilizaciones del mismo.
US6008011A (en) 1991-10-31 1999-12-28 Whitehead Institute For Biomedical Research TGF-β type II receptor cDNAs
CA2122491A1 (en) 1991-10-31 1993-05-13 Herbert Y. Lin Tgf-.beta. type receptor cdnas and uses therefor
JP3854307B2 (ja) 1991-12-04 2006-12-06 ザ バーナム インスティテュート 細胞外マトリックスの蓄積を防止するためのトランスフォーミング増殖因子βの阻害
GB9205800D0 (en) 1992-03-17 1992-04-29 British Tech Group Treatment of fibrotic disorders
AU3920693A (en) 1992-03-18 1993-10-21 General Hospital Corporation, The Four novel receptors of the TGF-beta receptor family
WO1993019783A1 (en) 1992-04-01 1993-10-14 The Whittier Institute For Diabetes And Endocrinology Methods of inhibiting or enhancing scar formation in the cns
US5869462A (en) 1992-09-10 1999-02-09 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of proliferation of vascular smooth muscle cell
US5821234A (en) 1992-09-10 1998-10-13 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of proliferation of vascular smooth muscle cell
AU5587094A (en) 1992-10-26 1994-05-24 Kirin Brewery Company, Limited Method for producing large latent transforming growth factor-beta complexes and large latency associated peptide
CA2146973C (en) * 1992-10-29 2008-09-02 Patricia R. Segarini Uses of tgf-.beta. receptor fragment as a therapeutic agent
US5830847A (en) 1992-10-30 1998-11-03 Hsc Research & Development Limited Partnership Soluble TGF-β-binding endoglin polypeptides and homodimers
AU671491B2 (en) 1992-12-18 1996-08-29 F. Hoffmann-La Roche Ag N-oxycarbonyl substituted 5'-deoxy-5-fluorcytidines
US6455689B1 (en) 1993-04-30 2002-09-24 Biognostik Gesellschaft für Biomolekulare Diagnostik mbH Antisense-oligonucleotides for transforming growth factor-β (TGF-β)
AU6984594A (en) 1993-06-15 1995-01-17 Hun Taeg Chung Anti-sense oligodeoxynucleotide to fibrogenic cytokines and use thereof
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
JPH09512910A (ja) 1994-05-04 1997-12-22 マウント・サイナイ・ホスピタル・コーポレイション ＴＧＦ−βスーパーファミリーのサイトカインの変調因子およびそのアッセイ方法
US5772995A (en) 1994-07-18 1998-06-30 Sidney Kimmel Cancer Center Compositions and methods for enhanced tumor cell immunity in vivo
CA2156767A1 (en) 1994-08-25 1996-02-26 Kenichi Matsunaga Binding agent for growth factor
JPH08119984A (ja) 1994-08-31 1996-05-14 Nkk Corp ストレプトミセス属放線菌及びこの菌由来のＴＧＦ−β 阻害剤
US5834248A (en) 1995-02-10 1998-11-10 Millennium Pharmaceuticals Inc. Compositions and methods using rchd534, a gene uregulated by shear stress
US5824655A (en) 1995-02-15 1998-10-20 The University Of Utah Anti-transforming growth factor-β gene therapy
US5824299A (en) 1995-06-22 1998-10-20 President & Fellows Of Harvard College Modulation of endothelial cell proliferation with IP-10
GB9601081D0 (en) 1995-10-06 1996-03-20 Cambridge Antibody Tech Specific binding members for human transforming growth factor beta;materials and methods
WO1997040848A1 (en) 1996-04-30 1997-11-06 Genzyme Corporation Use of prolactin as a tgf-beta antagonist
JPH1067674A (ja) 1996-06-19 1998-03-10 Advanced Sukin Res Kenkyusho:Kk 細胞外マトリツクスの異常蓄積抑制剤
US5807708A (en) 1996-07-30 1998-09-15 Millennium Pharmaceuticals, Inc. Conservin nucleic acid molecules and compositions
AU3215597A (en) 1996-08-30 1998-03-19 Biomeasure Incorporated Method of inhibiting fibrosis with a somatostatin agonist
AU740052B2 (en) 1996-10-25 2001-10-25 Ethicon Inc. Anti-fibrotic agent assay
US5948639A (en) 1997-04-10 1999-09-07 Millennium Pharmaceuticals, Inc. TGF-β pathway genes
US20020102208A1 (en) 1999-03-01 2002-08-01 Paul Chinn Radiolabeling kit and binding assay
KR100717916B1 (ko) * 2000-02-28 2007-05-11 아방티 파르마 소시에테 아노님 캄프토테신 및 피리미딘 유도체를 포함하는 암 치료용 조성물
KR20060127409A (ko) * 2003-11-13 2006-12-12 제넨테크, 인크. 종양 치료 방법 및 스크리닝 검정
WO2005059133A2 (en) * 2003-12-19 2005-06-30 Antisense Pharma Gmbh Combination therapy associating a tgf-breta antagonist with a chemiotherapeutic agent
CA2561686C (en) * 2004-03-31 2014-12-02 Genentech, Inc. Humanized anti-tgf-beta antibodies
MX2007005763A (es) * 2004-11-18 2007-07-20 Squibb Bristol Myers Co Perla recubierta enterica que comprende ixabepilona, y preparacion y administracion de la misma.
CN101163502A (zh) 2005-02-08 2008-04-16 根茨美公司 针对TGFβ的抗体
WO2007140299A2 (en) * 2006-05-25 2007-12-06 Bristol-Myers Squibb Company Use of ixabepilone in combination with cyp3a4 inhibitors for pharmaceuticals
EP2164856A1 (en) 2007-06-01 2010-03-24 Synthon B.V. Processes related to making capecitabine
DE102008002395A1 (de) * 2008-06-12 2009-12-17 Biotronik Vi Patent Ag Wirkstoffbeladenes Implantat
TR201816180T4 (tr) * 2010-03-12 2018-11-21 Genzyme Corp Meme kanserini tedavi etmek için kombinasyonlu tedavi.

Also Published As

Publication number Publication date
CY1117831T1 (el) 2017-05-17
WO2011112609A1 (en) 2011-09-15
EP2835053A1 (en) 2015-02-11
JP2016164174A (ja) 2016-09-08
EP3117709B1 (en) 2018-08-01
PL2835053T3 (pl) 2016-12-30
HUE040107T2 (hu) 2019-02-28
US10507242B2 (en) 2019-12-17
PT2835053T (pt) 2016-07-14
EP2544541A1 (en) 2013-01-16
EP3406141B1 (en) 2020-10-14
US20150086547A1 (en) 2015-03-26
JP6289528B2 (ja) 2018-03-07
HK1206936A1 (en) 2016-01-22
TR201816180T4 (tr) 2018-11-21
ME02464B (me) 2017-02-20
DK2835053T3 (en) 2016-08-15
HRP20160932T1 (hr) 2016-10-07
JP5917418B2 (ja) 2016-05-11
DK3117709T3 (en) 2018-11-26
PT3117709T (pt) 2018-11-15
LT3117709T (lt) 2018-11-26
US20170319691A1 (en) 2017-11-09
SMT201600253B (it) 2016-08-31
SI3117709T1 (sl) 2018-12-31
US9539325B2 (en) 2017-01-10
EP3406141A1 (en) 2018-11-28
US20130034549A1 (en) 2013-02-07
ES2694288T3 (es) 2018-12-19
EP2544541A4 (en) 2013-07-31
EP2544541B1 (en) 2014-10-08
RS54972B1 (sr) 2016-11-30
US8911736B2 (en) 2014-12-16
HUE027831T2 (en) 2016-11-28
ES2584433T3 (es) 2016-09-27
RS57942B1 (sr) 2019-01-31
EP2835053B1 (en) 2016-04-27
EP3117709A1 (en) 2017-01-18
JP2013522210A (ja) 2013-06-13
SI2835053T1 (sl) 2016-09-30
HRP20181757T1 (hr) 2019-01-25

Similar Documents

Publication Publication Date Title
IL272206A (en) Combined treatment for cancer
IL258612B (en) An anti-angiogenic drug for the treatment of ovarian cancer
ZA201205003B (en) Methods for treating breast cancer
GB2495841B (en) Phytocannabinoids for use in the treatment of breast cancer
IL243741A0 (en) Anti-angiogenic therapy for the treatment of breast cancer
SG11201501653RA (en) Methods for the treatment of locally advanced breast cancer
PH12014500248A1 (en) Treatment of breast cancer
EP2751267A4 (en) METHOD FOR THE TREATMENT OF BREAST CANCER
SG10201508495VA (en) Combination treatment of cancer
SI2804599T1 (sl) Kombinirana terapija za zdravljenje raka
HRP20181757T1 (hr) Kombinirana terapija za liječenje raka dojke
IL222958A0 (en) Cancer treatment
ZA201300762B (en) Novel combination therapy for the treatment of cancer
GB201106630D0 (en) Cancer therapy
GB201301168D0 (en) Cancer treatment
GB201020513D0 (en) Cancer therapy
ZA201208905B (en) Cancer therapy method
GB201019034D0 (en) Treatment for tumors
IL233495A0 (en) Combination for cancer treatment
ZA201307677B (en) Anti-angiogenesis therapy for the treatment of ovarian cancer
GB201017356D0 (en) Combination treatment of cancer
GB0921102D0 (en) Cancer Therapy
GB0913603D0 (en) Cancer therapy
GB201118220D0 (en) Cancer therapy
GB201017354D0 (en) Treatment of cancer